SEP 9, 2026 · JOURNAL ARTICLE
Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade
Frontiers in Oncology
Real-world observational study confirming efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer, consistent with historical trial data but limited by small single-centre sample and descriptive design.
Important Confirmatory EvidenceAbdul Shahid Poovathum ParambilArun VasudevanBreast Cancer Treatment Studies
Reported
Primary endpoint: pCR rate overall51.4%
pCR rate, SC group44.2%
pCR rate, IV group68.2%